Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

Peptide therapy enhances targeted medicine, utilizing specific peptides for effective treatment of cancer, metabolic disorders, and neurodegenerative diseases.

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...